Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. | Mestag ...

Ken Frazier and Ken Chenault said companies retreating from DEI will limit equal opportunities for disadvantaged Americans.

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

On Wednesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $110.42 which represents a decrease of $-1.11 or -1.00% from the prior close of $111.53. The stock opened at $111 and touched ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility ...